MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial
News
Doctors and nurses produce roadmap to future-proof healthcare
Report uses input from healthcare professionals to highlight training and support needs, while also warning about departures
NHS to improve cancer treatment using Elekta software
ProKnow was chosen to enable healthcare providers to benchmark treatment metrics against best practice and support clinical excellence
New report on tackling ethnic inequalities in diabetes care
Charter for Change examines reasons for inequalities and sets out recommendations to improve diabetes care
Sanofi and IGM Biosciences team up to develop antibody agonists
Collaboration will involve the development of new class IgM antibodies with a view to gaining market approval
Santen launches new educational eyecare site for patients in UK
Digital health boost as new website focuses on dry eye disease, which currently affects one in four people across the UK
Google Cloud and Babylon Health collaborate to improve patient care
Collaboration between Babylon Health and tech giant seeks to speed up historically slow patient access to data
Stalicla completes phase 1b trials into precision medicine for autism spectrum disorder
STP1 has demonstrated good safety and tolerability profiles, while also showing positive results for neurological function
Jazz Pharmaceuticals reveals new manufacturing facility for cannabis-based medicines
The site in Kent will support the manufacture of regulatory approved cannabis-based medicines while also leveraging environmental practices
Poolbeg signs AI deal to advance human challenge data
Collaboration will focus on AI analysis of flu progression, immune responses and the development of new vaccines
UK’s first digital health training programme for all NHS frontline staff
The platform to build a digital-ready frontline workforce will be available to all NHS and social care staff
Huma and AstraZeneca collaborate to advance digital innovation
Digital-first patient care is a priority as the companies join forces to improve patients’ lives
NHS contacting five million people for fourth COVID-19 vaccination
Groups including those aged over 75-years-old, care home residents and the immunocompromised will be entitled to a fourth jab
Takeda’s Exkivity receives MHRA conditional marketing authorisation
Approval of Exkivity could mean NHS access to ground-breaking treatment for patients with rare lung cancer
NICE recommends Biomarin’s Vimizim for patients with rare life-limiting metabolic disorder
Patients with a life-limiting skeletal condition welcome availability of elosulfase alfa on the NHS
